ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling

Blood

Volumn 117, Issue 9, 2011, Pages 2658-2667

  Kuster, Lilian ^a   Grausenburger, Reinhard ^a   Fuka, Gerhard ^a   Kaindl, Ulrike ^a   Krapf, Gerd ^a   Inthal, Andrea ^a   Mann, Georg ^a   Kauer, Maximilian ^a   Rainer, Johannes ^b   Kofler, Reinhard ^b   Hall, Andrew ^c   Metzler, Markus ^d   Meyer, Lüder Hinrich ^e   Meyer, Claus ^f   Harbott, Jochen ^g   Marschalek, Rolf ^f   Strehl, Sabine ^a   Haas, Oskar A ^a   Panzer Grümayer, Renate ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 MODIFYING FACTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; NUCLEAR RECEPTOR NR3C1; PROTEIN BCL 2; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA COPY NUMBER ABERRATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE DOSAGE; HUMAN; LEUKEMIA RELAPSE; MALE; MISMATCH REPAIR; MOLECULAR CLONING; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 79953090054     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-275347     Document Type: Article

References (51)

1. Romana SP, Mauchauffe M, Le Coniat M, et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood. 1995; 85(12):3662-3670.
2. Frost BM, Forestier E, Gustafsson G, et al. Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia. Blood. 2004; 104(8):2452-2457. (Pubitemid 39331847)
3. Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96(3):1094-1099. (Pubitemid 30616878)
4. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008; 111(9):4477-4489.
5. Fasching K, Konig M, Hettinger K, et al. MRD levels during the first months of treatment indicate relapses in children with t(12;21)-positive ALL. Leukemia. 2000;14(9):1707-1708.
6. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4):771-782.
7. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(15): 1535-1548.
8. Loh ML, Goldwasser MA, Silverman LB, et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood. 2006;107(11): 4508-4513. (Pubitemid 43801379)
9. Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials: Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin- Frankfurt-Munster Study Group. Blood. 1997; 90(2):571-577. (Pubitemid 27299096)
10. ui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-1043.
11. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer. 2003;3(9):639-649. (Pubitemid 37328819)
12. Raynaud S, Cave H, Baens M, et al. The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood. 1996;87(7):2891-2899. (Pubitemid 26102240)
13. Kuiper RP, Schoenmakers EF, van Reijmersdal SV, et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia. 2007;21(6):1258-1266. (Pubitemid 46831815)
14. Ford AM, Fasching K, Panzer-Grumayer ER, Koenig M, Haas OA, Greaves MF. Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes. Blood. 2001;98(3):558-564.
15. Peham M, Konrad M, Harbott J, Konig M, Haas OA, Panzer-Grumayer ER. Clonal variation of the immunogenotype in relapsed ETV6/ RUNX1-positive acute lymphoblastic leukemia indicates subclone formation during early stages of leukemia development. Genes Chromosomes Cancer. 2004;39(2):156-160. (Pubitemid 38056089)
16. Konrad M, Metzler M, Panzer S, et al. Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone. Blood. 2003;101(9):3635- 3640. (Pubitemid 36857953)
17. Metzler M, Mann G, Monschein U, et al. Minimal residual disease analysis in children with t(12; 21)-positive acute lymphoblastic leukemia: comparison of Ig/TCR rearrangements and the genomic fusion gene. Haematologica. 2006; 91(5):683-686. (Pubitemid 43799470)
18. Panzer-Grumayer ER, Cazzaniga G, van der Velden VH, et al. Immunogenotype changes prevail in relapses of young children with TEL-AML1- positive acute lymphoblastic leukemia and derive mainly from clonal selection. Clin Cancer Res. 2005;11(21):7720-7727. (Pubitemid 41611614)
19. Zuna J, Ford AM, Peham M, et al. TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin Cancer Res. 2004;10(16):5355-5360. (Pubitemid 39100471)
20. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446(7137):758-764. (Pubitemid 46582031)
21. Kawamata N, Ogawa S, Zimmermann M, et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood. 2008;111(2):776-784.
22. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009; 41(11):1243-1246.
23. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008; 322(5906):1377-1380. (Pubitemid 352775249)
24. Yang JJ, Bhojwani D, Yang W, et al. Genomewide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood. 2008; 112(10):4178-4183.
25. Kawamata N, Ogawa S, Seeger K, et al. Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia. Int J Oncol. 2009;34(6): 1603-1612.
26. Csinady E, van der Velden VH, Joas R, et al. Chromosome 14 copy number-dependent IGH gene rearrangement patterns in high hyperdiploid childhood B-cell precursor ALL: implications for leukemia biology and minimal residual disease analysis. Leukemia. 2009;23(5):870-876.
27. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004;5(4):557-572. (Pubitemid 41180205)
28. Krapf G, Kaindl U, Kilbey A, et al. ETV6/RUNX1 abrogates mitotic checkpoint function and targets its key player MAD2L1. Oncogene. 2010;29(22): 3307-3312.
29. Ploner C, Rainer J, Niederegger H, et al. The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia. Leukemia. 2008;22(2):370-377. (Pubitemid 351250542)
30. Inthal A, Krapf G, Beck D, et al. Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia. Clin Cancer Res. 2008; 14(22):7196-7204.
31. Irving JA, Bloodworth L, Bown NP, Case MC, Hogarth LA, Hall AG. Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis. Cancer Res. 2005;65(88): 3053-3058.
32. Graf Einsiedel H, Taube T, Hartmann R, et al. Deletion analysis of p16(INKa) and p15(INKb) in relapsed childhood acute lymphoblastic leukemia. Blood. 2002;99(12):4629-4631. (Pubitemid 34627237)
33. Maloney KW, McGavran L, Odom LF, Hunger SP. Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood. 1999;93(7):2380-2385. (Pubitemid 29153642)
34. Matheson EC, Hall AG. Assessment of mismatch repair function in leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia. Carcinogenesis. 2003;24(1):31-38. (Pubitemid 36193193)
35. Pinon JD, Labi V, Egle A, Villunger A. Bim and Bmf in tissue homeostasis and malignant disease. Oncogene. 2008;27(suppl 1):S41-S52.
36. Labi V, Erlacher M, Kiessling S, et al. Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates gamma irradiation-induced thymic lymphoma development. J Exp Med. 2008; 205(3):641-655. (Pubitemid 351439310)
37. Schindler JW, Van Buren D, Foudi A, et al. TELAML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell. 2009;5(1):43-53.
38. Tsai AG, Lu H, Raghavan SC, Muschen M, Hsieh CL, Lieber MR. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell. 2008;135(6):1130-1142.
39. Kitagawa Y, Inoue K, Sasaki S, et al. Prevalent involvement of illegitimate V(D)J recombination in chromosome 9p21 deletions in lymphoid leukemia. J Biol Chem. 2002;277(48):46289-46297.
40. Mullighan CG, Miller CB, Radtke I, et al. BCRABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110-114. (Pubitemid 351630327)
41. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(7191):470-480.
42. van Zutven LJ, van Drunen E, de Bont JM, et al. CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia. Leukemia. 2005;19(7):1281-1284. (Pubitemid 40946020)
43. Stams WA, den Boer ML, Beverloo HB, et al. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)- positive pediatric acute lymphoblastic leukemia. Clin Cancer Res. 2005;11(8):2974-2980.
44. Patel N, Goff LK, Clark T, et al. Expression profile of wild-type ETV6 in childhood acute leukaemia. Br J Haematol. 2003;122(1):94-98. (Pubitemid 36819343)
45. Zhang Y, Adachi M, Kawamura R, Imai K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ. 2006;13(1):129-140.
46. Heerema NA, Sather HN, Sensel MG, et al. Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia. Cancer. 2002;94(4):1102-1110. (Pubitemid 34150866)
47. Irving JA, Minto L, Bailey S, Hall AG. Loss of heterozygosity and somatic mutations of the glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course. Cancer Res. 2005;65(21):9712-9718. (Pubitemid 41541447)
48. Gruber G, Carlet M, Turtscher E, et al. Levels of glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-induced leukemia apoptosis. Leukemia. 2009;23(4):820-823.
49. Eckert C, Biondi A, Seeger K, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet. 2001;358(358):1239-1241. (Pubitemid 33010852)
50. Labi V, Grespi F, Baumgartner F, Villunger A. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ. 2008;15(6):977-987.
51. Brown P, Hunger SP, Smith FO, Carroll WL, Reaman GH. Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Rev Hematol. 2009;2(9):145-158.